0000899243-22-034087.txt : 20221024
0000899243-22-034087.hdr.sgml : 20221024
20221024191007
ACCESSION NUMBER: 0000899243-22-034087
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20221020
FILED AS OF DATE: 20221024
DATE AS OF CHANGE: 20221024
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Herron Jennifer Lyn
CENTRAL INDEX KEY: 0001675774
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35420
FILM NUMBER: 221326908
MAIL ADDRESS:
STREET 1: C/O GENOCEA BIOSCIENCES, INC.
STREET 2: 100 ACORN PARK DRIVE 5TH FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02140
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ChemoCentryx, Inc.
CENTRAL INDEX KEY: 0001340652
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 943254365
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 835 INDUSTRIAL ROAD
STREET 2: SUITE 600
CITY: SAN CARLOS
STATE: CA
ZIP: 94070
BUSINESS PHONE: 650-210-2900
MAIL ADDRESS:
STREET 1: 835 INDUSTRIAL ROAD
STREET 2: SUITE 600
CITY: SAN CARLOS
STATE: CA
ZIP: 94070
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-10-20
1
0001340652
ChemoCentryx, Inc.
CCXI
0001675774
Herron Jennifer Lyn
C/O CHEMOCENTRYX, INC.
835 INDUSTRIAL ROAD, SUITE 600
SAN CARLOS
CA
94070
1
0
0
0
Common Stock
2022-10-20
4
D
0
17237
D
0
D
Reflects the disposition of securities pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 3, 2022, among Amgen Inc. ("Parent"), Carnation Merger Sub, Inc. ("Merger Sub") and ChemoCentryx, Inc. (the "Company"), pursuant to which, on October 20, 2022, Merger Sub merged with and into the Company, with the Company surviving the merger as a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger (the "Effective Time"), each issued and outstanding share of common stock, par value $0.001 per share, of the Company (collectively, the "Shares," and each such share, a "Share") (other than any such Shares (i) held by the Company as treasury stock or owned by Parent or Merger Sub, (ii) held by any subsidiary of the Company or Parent (other than Merger Sub) or (iii) as to which appraisal rights have been properly exercised,
(Continued from Footnote 1) and not withdrawn, in accordance with the Delaware General Corporation Law) was thereupon canceled and converted into the right to receive $52.00 in cash, without interest (the "Merger Consideration"). As a result of the Merger, the Reporting Person no longer beneficially owns, directly or indirectly, any Shares.
/s/ Susan M. Kanaya, as Attorney-in-Fact
2022-10-20